Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $850.00 | Overweight | Barclays |
| 10/31/2025 | $700.00 | Hold → Buy | Stifel |
| 10/1/2025 | $720.00 | Neutral | UBS |
| 8/5/2025 | $545.00 → $785.00 | Buy | BTIG Research |
| 7/1/2025 | $625.00 | Buy | Jefferies |
| 12/2/2024 | $500.00 | Outperform | Leerink Partners |
| 7/25/2024 | $580.00 | Buy | BTIG Research |
| 1/30/2024 | $525.00 | Overweight → Neutral | Piper Sandler |
A fully connected imaging ecosystem – centralized access, integrated workflows, and AI-powered imaging to accelerate diagnosis and elevate care IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the launch of the ImageVue™ DR50 Plus Digital Imaging System, its most advanced diagnostic imaging solution for veterinary practices. Designed to set a new standard, the system combines high definition, AI-powered imaging at the lowest dose of radiation – reducing exposure by up to 25% compared to IDEXX's current best-in-class ImageVue™ DR50 system1 and up to 60% compared to other veterinary imaging solutions2. Coupled with IDEXX's connected end-t
Cancer Dx expansion and inVue Dx FNA combine preventive screening and rapid, in-clinic diagnosis, enabling veterinarians and pet owners to act with confidence IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced two major advancements in veterinary cancer diagnostics: the expansion of its IDEXX Cancer Dx™ Panel to include canine mast cell tumor detection, starting mid-year 2026 in North America, and the rollout of FNA cytology on the IDEXX inVue Dx™ Cellular Analyzer, as of late Q4 2025. Together, these innovations will deliver earlier insights and rapid, in-clinic answers, helping veterinary teams guide timely treatment decisions. With mas
Michael Erickson, PhD, to Succeed Jay Mazelsky as President and CEO; Mazelsky to Serve as Executive Chair of the Board of Directors IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the promotion of Michael (Mike) Erickson, PhD, to President and Chief Executive Officer, effective May 12, 2026, at which time Jonathan (Jay) Mazelsky, President and CEO, will transition to the role of Executive Chair of IDEXX's Board of Directors (the "Board"). Mr. Mazelsky has announced his intention to retire from the Company immediately following the Company's annual meeting of shareholders in May 2027, and will work closely with Dr. Erickson throughout t
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
Barclays initiated coverage of IDEXX Labs with a rating of Overweight and set a new price target of $850.00
Stifel upgraded IDEXX Labs from Hold to Buy and set a new price target of $700.00
UBS initiated coverage of IDEXX Labs with a rating of Neutral and set a new price target of $720.00
Former Modernizing Medicine sales leader joins Bonsai to accelerate growth of its agentic AI platform for healthcare practices. Bonsai Health, the agentic AI platform automating complex healthcare workflows, today announced that Rick Trefzger has joined the company as Chief Revenue Officer (CRO). Trefzger joins Bonsai after nearly 11 years at Modernizing Medicine (ModMed), where he was an early employee and served as vice president of sales, helping scale the company into the leading specialty-specific EHR platform serving dermatology, ophthalmology, orthopedics, gastroenterology, and other core specialties. During his tenure, ModMed grew into one of the most widely adopted specialty te
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Directors, effective October 6, 2025. "We are extremely pleased to welcome Karen to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Karen is a highly accomplished executive with deep B2B, SaaS software and AI experience gained through building and running software and technology companies at various lifecycle stages. We are confident that her extensive professional experience and skills will complement those of our other Board members and contribute to our Board's overal
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Jay is an accomplished executive who brings extensive strategic thinking and financial leadership experience, along with investor perspective, from his tenure leading State Street during a period of global growth and technological transformation. Given his substantial public company board and corporate governance experience and his unique backgro
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telep
Achieves third quarter revenue growth of 13% as reported and 12% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. Strong organic revenue growth was supported by IDEXX execution and commercial performance, reflecting benefits from IDEXX's innovation, including over 1,700 IDEXX inVue Dx™ placements. Delivers EPS of $3.40, an increase of 21% as reported and 15% on a comparable basis, including operating margin expansion of 100 basis points as reported and 120 basis points on a comparable basis. Increases 2025 revenue guidance to $4,270 million - $4,300 million, an increase of $43 million or ~1% at midpoint, reflecting stronger CAG Diagnosti
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 third quarter financial results for Monday, November 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen
SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)
SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)
SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)